Lexaria Bioscience Corp. (NASDAQ: LEXX) announced today that it has extended its Material Transfer Agreement (MTA) with an undisclosed pharmaceutical company, referred to as PharmaCO, through December 31, 2026. The original agreement, entered into on August 30, 2024, was designed to evaluate Lexaria's DehydraTECH™ technology in a pre-clinical setting. The extension allows time for PharmaCO to receive and review Lexaria's 2026 research and development results related to GLP-1 drugs, which are used to treat conditions like diabetes and obesity.
Under the extended MTA, the temporary exclusive license remains active and in force. The two parties will continue their relationship and contemplate additional strategic planning discussions with PharmaCO's human clinical and business development teams. This development signals potential progress toward licensing or collaboration agreements that could bring Lexaria's drug delivery technology to market.
Over the past 12 months, Lexaria has advanced its GLP-1 development program with three key studies: Human Study #7, Animal Study #1, and Animal Study #2. All studies are within the GLP-1 sector and are designed to provide comprehensive evidence to support additional collaboration and potential licensing of Lexaria's technology. The studies are fully funded with existing corporate resources, and results are expected during Q3 and Q4 of this calendar year.
Lexaria's DehydraTECH platform is a patented drug delivery formulation and processing technology that improves oral drug absorption, reduces side-effects, and enhances delivery across the blood-brain barrier. The company holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, visit www.lexariabioscience.com.
The extension of the MTA is important because it indicates sustained interest from a pharmaceutical partner in Lexaria's technology, particularly in the high-demand GLP-1 drug market. If successful, the technology could improve the efficacy and tolerability of oral GLP-1 therapies, potentially benefiting patients and expanding market opportunities. However, the company cautions that forward-looking statements involve risks and uncertainties, including regulatory approvals, scientific discovery, and the ability to maintain collaborations.
